Intermune, Inc. is a bio pharmaceutical company that specializes in developing innovative therapies for patients with serious and life-threatening diseases. The company has a portfolio of drugs that treat respiratory, inflammation, and fibrotic diseases. Intermune, Inc. is committed to providing better treatment options for patients, and their dedication to research and development has led to the creation of cutting-edge treatments. Uses Intermune, Inc. has a portfolio of drugs that treat respiratory, inflammation, and fibrotic diseases. One of their most popular drugs is Esbriet, which is used to treat idiopathic pulmonary fibrosis (IPF). IPF is a progressive disease that causes scarring of the lungs, leading to difficulty breathing. Esbriet helps slow down the disease progression, improving patients' quality of life. Dosage The recommended dosage for Esbriet is three capsules, three times a day, for a total of nine capsules per day. The capsules should be taken with food to avoid stomach upset. The treatment is continuous and should be taken for as long as the doctor prescribes. Side Effects Esbriet may cause side effects, although not all patients will experience them. Common side effects include nausea, fatigue, diarrhea, and upset stomach. Serious side effects may occur, including liver problems, hypersensitivity, and bleeding. Patients should contact their doctor if they experience any unusual symptoms while taking Esbriet. Interactions Intermune, Inc. advises that patients should inform their doctor of any medications they are taking, including prescription drugs, over-the-counter medication, or herbal supplements. Esbriet may interact with other drugs, including anticoagulants, anti-inflammatory drugs, and immunosuppressive medication. Generic Intermune, Inc. has developed Esbriet, and it is currently the only brand-name drug on the market for treating IPF. However, some other generics are currently in the pipeline, and they are expected to launch shortly. Patients may choose to use generic versions of the drug when they become available, as they are expected to be significantly less expensive than the brand-name version. Demographic Esbriet is primarily used to treat IPF, which is a rare disease that affects older adults aged 50 to 70 years. The disease is more prevalent in men than women and is most commonly diagnosed in people who have a history of smoking. Patients of all ethnicities can develop IPF, although it is most common in Caucasians. Conclusion Intermune, Inc. has made significant contributions to the treatment of serious and life-threatening diseases. Their dedication to research and innovation has resulted in the development of cutting-edge therapies, including Esbriet. Esbriet has been approved to treat IPF, helping patients improve their quality of life and slow down the progression of the disease. As with any medication, patients should always follow instructions from their doctor and report any unusual symptoms they experience while taking Esbriet.